Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium
Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium
INTRODUCTION: Growth factors such as keratinocyte growth factor-2 (KGF-2) and transforming growth factor-beta (TGF-β) are important immunoregulatory and epithelial growth factors. They are also potential therapeutic proteins for inflammatory bowel disease. However, owing to protein instability in the upper gastrointestinal tract, it is difficult to achieve therapeutic levels of these proteins in the injured colon when given orally. Furthermore, the short half-life necessitates repeated dosage with large amounts of the growth factor, which may have dangerous side effects, hence the importance of temporal and spatial control of growth factor delivery.
METHODS: The human commensal gut bacterium, Bacteroides ovatus, was genetically engineered to produce human KGF-2 or TGF-β1 (BO-KGF or BO-TGF) in a regulated manner in response to the dietary polysaccharide, xylan. The successful application of BO-KGF or BO-TGF in the prevention of dextran sodium sulphate induced murine colitis is presented here.
RESULTS: This novel drug delivery system had a significant prophylactic effect, limiting the development of intestinal inflammation both clinically and histopathologically. The ability to regulate heterologous protein production by B ovatus using xylan is both unique and an important safety feature of this drug delivery system.
CONCLUSIONS: The use of genetically engineered B ovatus for the controlled and localised delivery of epithelial growth promoting and immunomodulatory proteins has potential clinical applications for the treatment of various diseases targeting the colon.
Animals, Anti-Inflammatory Agents/administration & dosage, Bacteroides, Bacteroides Infections/drug therapy, Colitis/chemically induced, Dextran Sulfate, Drug Delivery Systems, Fibroblast Growth Factor 10/administration & dosage, Genetic Engineering, Irritants, Male, Mice, Mice, Inbred C57BL, Probiotics/administration & dosage, Transforming Growth Factor beta/administration & dosage, Xylans
235-40
Hamady, Z Z R
545a1c81-276e-4341-a420-aa10aa5d8ca8
May 2013
Hamady, Z Z R
545a1c81-276e-4341-a420-aa10aa5d8ca8
Hamady, Z Z R
(2013)
Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium.
Annals of The Royal College of Surgeons of England, 95 (4), .
(doi:10.1308/003588413X13511609958217).
Abstract
INTRODUCTION: Growth factors such as keratinocyte growth factor-2 (KGF-2) and transforming growth factor-beta (TGF-β) are important immunoregulatory and epithelial growth factors. They are also potential therapeutic proteins for inflammatory bowel disease. However, owing to protein instability in the upper gastrointestinal tract, it is difficult to achieve therapeutic levels of these proteins in the injured colon when given orally. Furthermore, the short half-life necessitates repeated dosage with large amounts of the growth factor, which may have dangerous side effects, hence the importance of temporal and spatial control of growth factor delivery.
METHODS: The human commensal gut bacterium, Bacteroides ovatus, was genetically engineered to produce human KGF-2 or TGF-β1 (BO-KGF or BO-TGF) in a regulated manner in response to the dietary polysaccharide, xylan. The successful application of BO-KGF or BO-TGF in the prevention of dextran sodium sulphate induced murine colitis is presented here.
RESULTS: This novel drug delivery system had a significant prophylactic effect, limiting the development of intestinal inflammation both clinically and histopathologically. The ability to regulate heterologous protein production by B ovatus using xylan is both unique and an important safety feature of this drug delivery system.
CONCLUSIONS: The use of genetically engineered B ovatus for the controlled and localised delivery of epithelial growth promoting and immunomodulatory proteins has potential clinical applications for the treatment of various diseases targeting the colon.
This record has no associated files available for download.
More information
Published date: May 2013
Keywords:
Animals, Anti-Inflammatory Agents/administration & dosage, Bacteroides, Bacteroides Infections/drug therapy, Colitis/chemically induced, Dextran Sulfate, Drug Delivery Systems, Fibroblast Growth Factor 10/administration & dosage, Genetic Engineering, Irritants, Male, Mice, Mice, Inbred C57BL, Probiotics/administration & dosage, Transforming Growth Factor beta/administration & dosage, Xylans
Identifiers
Local EPrints ID: 455113
URI: http://eprints.soton.ac.uk/id/eprint/455113
ISSN: 0035-8843
PURE UUID: 63933808-8f7d-46e4-9339-4eec231b7556
Catalogue record
Date deposited: 10 Mar 2022 17:30
Last modified: 17 Mar 2024 04:12
Export record
Altmetrics
Contributors
Author:
Z Z R Hamady
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics